A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Inclusion Criteria:

Parts 1-5: Have an Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1
Parts 1-5: Has thyroid function laboratory values within normal range
Parts 1-5: Females of childbearing potential must have a negative serum pregnancy test
Parts 1-5: Willing and able to adhere to the prohibitions and restrictions specified in this protocol
For Part 2 only: Participants enrolled into Part 2 must have tumor tissue available for correlative studies. Fresh tumor biopsy is preferred. Archival tissue must meet the following criteria: archival sections within 4 months of sectioning that have been stored at 2 degree to 8 degree Celsius in the dark or archival tumor blocks within 5 years of collection. Participants without tissues meeting the aforementioned archived tissue criteria must undergo a fresh biopsy
Parts 1 to 4: Have evaluable disease; For Part 5 only: at least 1 measurable lesion that can be accurately assessed at baseline by computed tomography (CT) and is suitable for repeated assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
For Part 5 only: Has a histologically or cytologically confirmed diagnosis of unresectable Stage III or Stage IV cutaneous or mucosal melanoma. Individuals with uveal or ocular melanoma are excluded
For Part 5 only: Up to 1 line of prior therapy for melanoma is allowed with the exception of prior anti-programmed-cell death receptor-1 (anti-PD-1) antibody, anti-PD-L1 antibody, or anti-PD-L2 antibody therapy
For Part 5 only- Participants enrolled into Part 5 must have tumor tissue available for central determination of PD-L1 status. The exception is participants who do not have sufficient tissue available for central testing, in which case a Sponsor-approved local assay may be accepted

Exclusion Criteria:

Has uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure (New York Heart Association class III-IV), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension or diabetes, or psychiatric illness/social situation that would limited compliance with study requirements
Has had prior treatment with an anti-Programmed-cell death receptor-1 (PD-1) antibody, anti-the ligand to programmed-cell death 1 (PD-L1) antibody or anti-the ligand to programmed-cell death 2 (PD-L2) antibody
Treatment with any local or systemic anti-neoplastic therapy, radiotherapy (excluding limited palliative radiation), or investigational anticancer agent within 14 days or 4 halflives, whichever is longer, up to a maximum wash-out period of 28 days prior to the initiation of study drug administration
Grade 3 or higher toxicity effects from previous treatment with immunotherapy
A female who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 5 months after the last dose of study drug